Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).

Helio Silva Sader Mariana Castanheira John H Kimbrough Valerie Kantro Rodrigo Elisandro Mendes

Published in: JAC-antimicrobial resistance (2023)

Aztreonam/avibactam activity was not adversely affected by clinically relevant CPEs. Our results support aztreonam/avibactam development to treat infections caused by CRE, including MBL producers.

Keyphrases

klebsiella pneumoniae
gram negative
healthcare
multidrug resistant
escherichia coli